Diabetes drug metformin takes on leukemia gene

NCT ID NCT07188740

Recruiting now Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This early-phase study tests whether metformin, a common diabetes drug, can lower the level of a harmful gene mutation (DNMT3A R882) in 30 people with acute leukemia who are in remission. Participants will take metformin pills for 6 months, and researchers will check if the mutation decreases. The goal is to see if this approach can help prevent the leukemia from coming back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Metformin
What this could lead to: If it works, this could point toward a way to lower the risk of leukemia relapse by targeting a specific gene mutation.
What could go wrong: This is a very early, small phase 1 trial with only 30 participants. It may not show a clear benefit, and metformin can cause side effects like stomach upset or low blood sugar.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DNMT3A GENE MUTATION

Contacts and locations

Locations

Blood Diseases Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.